Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Term is extended, borrowing capacity increases, financial flexibility improves, and interest rates remain relatively unchanged. TORONTO, Aug. 14, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces its financial results for the...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 Fiscal 2023 financial results on Thursday, August 10, 2023. The Company will hold a conference call...
John Welborn, Jr. is appointed Chair of the Board, succeeding Greg Gubitz, who is retiring John Hanna is appointed to the HLS Board as an independent director TORONTO, June 22, 2023 /CNW/ - HLS...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces voting results from its Annual Meeting...